GlassScriptPhysician profile
Jamil Ahmed
NPI 1588685879
$2,882.25
in general payments reported to CMS, 2019-2025
26 companies · $745 in 2025
The $745 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $41.05 · 2021: $332 · 2022: $346 · 2023: $459 · 2024: $664 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790 · Education: $76.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.44 |
| Education | $76.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $729.25 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $440.89 | 2019-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $190.81 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $179.97 | 2019-2023 | Veltassa |
| Horizon Therapeutics Plc | $175.24 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $167.84 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.21 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $109.58 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $108.06 | 2023-2025 | |
| Amgen INC. | $97.11 | 2024-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $68.23 | 2022-2023 | Lupkynis |
| W. L. Gore & Associates, INC. | $63.80 | 2024-2025 | Gore Viabahn Vbx Balloon Expandable Endo, Gore Viabahn Endoprosthesis |
| Akebia Therapeutics INC | $56.13 | 2021-2024 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $50.61 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $41.31 | 2019-2023 | Ultomiris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $37.35 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $37.28 | 2023-2024 | |
| Fresenius USA Marketing, INC. | $36.65 | 2019 | |
| Chiesi USA, INC. | $33.22 | 2024 | Elfabrio |
| Pharmacosmos Therapeutics INC. | $30.17 | 2024 | Monoferric |
| Ultragenyx Pharmaceutical INC. | $25.10 | 2024 | Crysvita |
| Mallinckrodt Hospital Products INC. | $24.25 | 2024 | Acthar |
| Genzyme Corporation | $17.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.20 | 2021 | |
| Nxstage Medical, INC. | $11.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamil Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.